| Patents for A61K 9 - Medicinal preparations characterised by special physical form (299,044) |
|---|
| 02/26/2013 | US8383611 Ciclesonide containing aqueous pharmaceutical composition |
| 02/26/2013 | US8383577 Octreotide implant having a release agent |
| 02/26/2013 | US8383548 Stable mixtures of microencapsulated and non-encapsulated pesticides |
| 02/26/2013 | US8383161 Radioopaque covalently crosslinked hydrogel particle implants |
| 02/26/2013 | US8383160 Compositions comprising solid particles entrapped in collapsed polymeric microspheres, and methods of making the same |
| 02/26/2013 | US8383159 Dosage forms having a microreliefed surface and methods and apparatus for their production |
| 02/26/2013 | US8383158 Methods and compositions to treat myocardial conditions |
| 02/26/2013 | US8383157 Lyophilized microspheres of nanofibrillar chitin, chitosan glycolate or cross-linked chitosan-hyaluronate, a plasticizer, and a second amino saccharide; reconstituted to homogenous suspension; antiseptics, wound healing agents; plastic surgery or dermocosmesis treatments |
| 02/26/2013 | US8383156 Coating for a medical device having an anti-thrombotic conjugate |
| 02/26/2013 | US8383155 Swellable dosage form comprising gellan gum |
| 02/26/2013 | US8383154 Swellable dosage form comprising gellan gum |
| 02/26/2013 | US8383152 Pharmaceutical dosage form |
| 02/26/2013 | US8383151 Pharmaceutical compositions of rifaximin |
| 02/26/2013 | US8383150 Granulate formulation of pirfenidone and pharmaceutically acceptable excipients |
| 02/26/2013 | US8383149 High enhancer-loading polyacrylate formulation for transdermal applications |
| 02/26/2013 | US8383148 Clay-based hemostatic agents and devices for the delivery thereof |
| 02/26/2013 | US8383146 Compositions for oral adminstration of active principles requiring masking of taste |
| 02/26/2013 | US8383135 Solid dosage form that promotes reliable oral, esophageal and GI transit |
| 02/26/2013 | US8383134 Biodegradable material based on opened starch |
| 02/26/2013 | US8383104 Thrombin-free biological adhesive and use thereof as a medicament |
| 02/26/2013 | US8383090 Cleansing composition based on oily substances |
| 02/26/2013 | US8383085 Methods of making iron-containing nanoparticles |
| 02/26/2013 | US8382936 Aqueous biopolymer-containing labeling adhesive |
| 02/26/2013 | CA2727899C Delayed release rasagiline formulation |
| 02/26/2013 | CA2617659C Use of hydroxybenzoic acid esters and analogues for the manufacture of a medicament for the prevention and treatment of virus infection |
| 02/26/2013 | CA2588943C Medical tape preparation |
| 02/26/2013 | CA2580659C Corticosteroid having low systemic absorption |
| 02/26/2013 | CA2564546C Aerosolized fosfomycin/aminoglycoside combination for the treatment of bacterial respiratory infections |
| 02/26/2013 | CA2550848C Combination of anticholinergics and inhibitors of phosphodiesterase type 4 for the treatment of respiratory diseases |
| 02/26/2013 | CA2543497C Controlled release analgesic suspensions |
| 02/26/2013 | CA2458966C Method and system for non-vascular sensor implantation |
| 02/26/2013 | CA2358570C Protonated/acidified nucleic acids and methods of use |
| 02/22/2013 | DE202006021153U1 Stabile, haltbare Granulate mit aktiven Mitteln Sturdy, durable granules with active agents |
| 02/21/2013 | WO2013026002A1 Steroid hormone delivery systems and methods of preparing the same |
| 02/21/2013 | WO2013025951A1 Fine dry particulate adenosine compositions and topical formulations including the same |
| 02/21/2013 | WO2013025941A1 Low protein percentage gelling compositions |
| 02/21/2013 | WO2013025940A1 Angiogenesis promoted by alpha-keratose |
| 02/21/2013 | WO2013025696A1 Ophthalmic formulations and processes for their preparation |
| 02/21/2013 | WO2013025545A2 Drug delivery systems and method of reducing foal infection by treating mares with gallium salts |
| 02/21/2013 | WO2013025449A1 Use of inorganic matrix and organic polymer combinations for preparing stable amorphous dispersions |
| 02/21/2013 | WO2013025442A2 Concentrated felbamate formulations for parenteral administration |
| 02/21/2013 | WO2013025418A1 Delivery system for specifically targeting cancer cells and method of use thereof |
| 02/21/2013 | WO2013025274A1 Vacuum -assisted preservation of biological products, in particular of vaccines |
| 02/21/2013 | WO2013024866A1 High concentration emulsion |
| 02/21/2013 | WO2013024710A1 Medicinal agent for evading immune response |
| 02/21/2013 | WO2013024663A1 Composition containing s-adenosyl-l-methionine with excellent storage stability |
| 02/21/2013 | WO2013024495A1 Pharmaceutical formulations of cabazitaxel |
| 02/21/2013 | WO2013024487A1 Anti- vitiligo composition |
| 02/21/2013 | WO2013024474A1 Polymorphs of preladenant |
| 02/21/2013 | WO2013024452A1 Method for encapsulating substances with formation of the capsule shell by interfacial reaction in the centrifugal reactor |
| 02/21/2013 | WO2013024425A1 Combinations of corroles and statins |
| 02/21/2013 | WO2013024411A1 Co-milled formulation of dronedarone |
| 02/21/2013 | WO2013024376A1 Compositions and methods for the treatment of atherothrombosis |
| 02/21/2013 | WO2013024373A1 Pharmaceutical composition comprising cefuroxime |
| 02/21/2013 | WO2013024362A2 Cardiovascular therapeutics |
| 02/21/2013 | WO2013024070A1 Pharmaceutical aerosol product for administration by oral or nasal inhalation |
| 02/21/2013 | WO2013024051A1 Sustained release composition of prostacyclin |
| 02/21/2013 | WO2013024036A1 Funny current (if) inhibitors for use in a method of treating and preventing heart failure in feline |
| 02/21/2013 | WO2013024023A1 Taste masked pharmaceutical composition |
| 02/21/2013 | WO2013024012A1 Medicinal skin protection composition with an active ingredient combination which improves the skin barrier |
| 02/21/2013 | WO2013023970A1 Pharmaceutical composition comprising 4-[4[[4-chloro-3-(trifluoromethyl)phenyl]carbamoylamino]phenoxy]-n-methylpyridine-2-carboxamide |
| 02/21/2013 | WO2013023882A1 Uridine and uridine analogues for treatment of specific lung diseases, namely copd and pulmonary fibrosis |
| 02/21/2013 | WO2013023856A1 Use of a polysaccharide polymer from the seeds of the tamarind seed in protecting against tobacco-associated damages |
| 02/21/2013 | WO2013023841A1 Method for producing and monitoring oral active ingredient films |
| 02/21/2013 | WO2013023775A1 Orodispersible films for the manufacturing of individualised medicine or for large scale production |
| 02/21/2013 | WO2013023250A1 Controlled-release formulation |
| 02/21/2013 | WO2012116073A3 Amphiphilic dendron-coils, micelles thereof and uses |
| 02/21/2013 | WO2011101828A8 A medicinal fusidic acid cream made using sodium fusidate and incorporating a biopolymer and betamethasone, and a process to make it |
| 02/21/2013 | US20130046392 System and method for attaching soft tissue to an implant |
| 02/21/2013 | US20130046283 Methods and intravascular treatment devices for treatment of atherosclerosis |
| 02/21/2013 | US20130046260 Disinfecting wound dressing and process for preparing such |
| 02/21/2013 | US20130045981 Aripiprazole complex formulation and method |
| 02/21/2013 | US20130045960 Abuse-Deterrent Pharmaceutical Compositions of Opiods and Other Drugs |
| 02/21/2013 | US20130045277 Biocompatible device |
| 02/21/2013 | US20130045276 Sustained release aminopyridine composition |
| 02/21/2013 | US20130045275 Sustained-release chitosan capsules comprising chitosan and phytic acid |
| 02/21/2013 | US20130045274 Bacteriotherapy for clostridium difficile colitis |
| 02/21/2013 | US20130045273 Methods for using nutritional supplements containing lipoic acids and sulfur containing compounds |
| 02/21/2013 | US20130045272 Agent for treating myelofibrosis |
| 02/21/2013 | US20130045271 Steroid hormone delivery systems and methods of preparing the same |
| 02/21/2013 | US20130045270 Method of use of stabilized growth factor in skin care |
| 02/21/2013 | US20130045269 Formulations and methods for wound treatment |
| 02/21/2013 | US20130045268 Abuse-resistant mucoadhesive devices for delivery of buprenorphine |
| 02/21/2013 | US20130045267 Methods of using agents that modulate claudin expression |
| 02/21/2013 | US20130045266 Method for preparing polymeric biomaterials having immobilized drug delivery system comprising bioactive molecules loaded particle carrier |
| 02/21/2013 | US20130045262 Sedative for external use, and sedative sheet, and textile, clothing, wall material, and hyperthermia equipment, brain vitalization sheet, brain vitalization small pillow |
| 02/21/2013 | US20130045253 Oral antidepressant formulation with reduced excipient load |
| 02/21/2013 | US20130045251 Pharmaceutical composition for improving solubility of prasugrel and its preparation method |
| 02/21/2013 | US20130045250 Suspension and cake composition containing carbostyryl derivative and silicone oil and/or silicone oil derivative |
| 02/21/2013 | US20130045249 Glycosaminoglycans |
| 02/21/2013 | US20130045248 Personal care compositions comprising an anti-irritation agent |
| 02/21/2013 | US20130045247 Fatty acid conjugates of quetiapine, process for making and using the same |
| 02/21/2013 | US20130045246 Enclosing materials in natural transport systems |
| 02/21/2013 | US20130045245 Apixaban formulations |
| 02/21/2013 | US20130045244 Modified adam disintegrin domain polypeptides and uses thereof |
| 02/21/2013 | US20130045243 NANOGENOMICS FOR MEDICINE: siRNA ENGINEERING |
| 02/21/2013 | US20130045242 Dextrin hydrogel for biomedical applications |
| 02/21/2013 | US20130045240 Combination therapy with nanoparticle compositions of taxane and hedgehog inhibitors |
| 02/21/2013 | US20130045239 Method for Modulating the Pharmacodynamic Effect of Orally Administered Guanylate Cyclase Receptor Agonists |
| 02/21/2013 | US20130045238 Emulsions for transdermal delivery |